Abstract
Alpha emitters have always promised to deliver potential benefit in cancer therapy. Using the example of radium-223 (Xofigo) and the paradigm of ionising radiation, this review looks at targeted alpha therapy from the perspective of a radiation oncologist.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have